Strong Start: Phibro Animal Health Reports Impressive Quarterly Results

Phibro Animal Health Corporation starts the fiscal year 2025 with a remarkable increase. CFO Glenn David presented excellent figures for the recently concluded first quarter, which ended on September 30, 2024. Revenues rose by 13% compared to the previous year, reaching USD 260.4 million. Notably, the animal health sector grew by 14%, and performance products saw a 27% increase. The company focuses on optimizing efficiency and further developing product innovations. Jack C. Bendheim, CEO and President, emphasized the strategic orientation, underscored by the recent acquisition of Zoetis's medicated feed additive business. This acquisition is expected to generate additional revenue of USD 200 million in the fiscal year 2025 and further strengthen the portfolio. Phibro highlights its past successes: the vaccine sector saw an increase of 22%, while mineral supplements rose by 5%. Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by an impressive 64%. Phibro sees itself well-prepared for the upcoming fiscal year and aims for a revenue increase of up to 8% in its updated forecast. Growth is expected to be supported by continued demand and strategic initiatives in the "Fiber Forward" area. These positive developments contribute to the optimism within the company, which is positioning itself for the future in animal health through continuous innovation and strategic acquisitions.